HomeCompareDSNKY vs KMB

DSNKY vs KMB: Dividend Comparison 2026

DSNKY yields 2.46% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DSNKY wins by $162.82M in total portfolio value· pulled ahead in Year 2
10 years
DSNKY
DSNKY
● Live price
2.46%
Share price
$18.24
Annual div
$0.45
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$162.87M
Annual income
$151,088,302.66
Full DSNKY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — DSNKY vs KMB

📍 DSNKY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDSNKYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DSNKY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DSNKY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DSNKY
Annual income on $10K today (after 15% tax)
$209.48/yr
After 10yr DRIP, annual income (after tax)
$128,425,057.26/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, DSNKY beats the other by $128,420,627.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DSNKY + KMB for your $10,000?

DSNKY: 50%KMB: 50%
100% KMB50/50100% DSNKY
Portfolio after 10yr
$81.46M
Annual income
$75,546,756.99/yr
Blended yield
92.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

DSNKY
No analyst data
Altman Z
3.3
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DSNKY buys
0
KMB buys
0
No recent congressional trades found for DSNKY or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDSNKYKMB
Forward yield2.46%5.25%
Annual dividend / share$0.45$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17%
Portfolio after 10y$162.87M$45.9K
Annual income after 10y$151,088,302.66$5,211.33
Total dividends collected$161.96M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: DSNKY vs KMB ($10,000, DRIP)

YearDSNKY PortfolioDSNKY Income/yrKMB PortfolioKMB Income/yrGap
1$11,193$492.89$11,314$613.68$121.00KMB
2← crossover$13,008$1,031.18$12,865$759.19+$143.00DSNKY
3$16,158$2,239.94$14,709$943.96+$1.4KDSNKY
4$22,490$5,200.86$16,919$1,180.17+$5.6KDSNKY
5$37,595$13,530.73$19,588$1,484.33+$18.0KDSNKY
6$82,504$42,277.45$22,838$1,879.06+$59.7KDSNKY
7$261,700$173,420.49$26,832$2,395.60+$234.9KDSNKY
8$1,308,212$1,028,193.03$31,788$3,077.63+$1.28MDSNKY
9$11,006,956$9,607,169.75$38,000$3,986.82+$10.97MDSNKY
10$162,865,746$151,088,302.66$45,872$5,211.33+$162.82MDSNKY

DSNKY vs KMB: Complete Analysis 2026

DSNKYStock

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Full DSNKY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this DSNKY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DSNKY vs SCHDDSNKY vs JEPIDSNKY vs ODSNKY vs KODSNKY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.